3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
High Risk Myeloid Malignancies
1
Hematologic Diseases
1
Interventions
pembrolizumab
105
Specimen Handling
55
Magnetic Resonance Spectroscopy
48
Biopsy
47
Nivolumab
39
Paclitaxel
35
Radiosurgery
30
Gemcitabine
30
Carboplatin
30
Cisplatin
23
Irinotecan
22
Ipilimumab
22
Cyclophosphamide
22
trastuzumab deruxtecan
21
Leucovorin
19
Capecitabine
19
Fluorouracil
18
Cetuximab
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
18
Pemetrexed
17
Fulvestrant
17
Drug Therapy
16
Docetaxel
16
Taxes
15
Oxaliplatin
15
olaparib
14
abemaciclib
14
Radiotherapy
14
atezolizumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Transplantation Conditioning
×
1 year
×
Clear all
NCT07627711
2026-06-04
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled
NCT07480928
2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled